In-hospital results of therapy with the NGLT-2 inhibitor dapagliflozin in patients with acute decompensation of heart failure: prospective randomized study

• DOI: 10.17816/cs622928
• Publication Date: 2024-04-10T15:51:17Z
• Authors: Omar M. Omarov; Grigorij G. Arabidze; Zaur S. Shogenov; Elena A. Petrik
• Keywords: Decompensation; Dapagliflozin

BACKGROUND: This study focuses on the development of new approaches to management patients with acute decompensation heart failure (ADHF) using sodium-glucose cotransporter type 2 (iHLT-2) inhibitors, particularly dapagliflozin, and its role in early treatment initiation.
 AIM: Our aim was determine predictors severe ADHF outcomes low left ventricular ejection fraction (LVEF) initiation iGLT-2 therapy (within first 24 h).
 MATERIALS AND METHODS: prospective randomized included a total 140 hospitalized between January 1 September 1, 2023. The were into two groups: group started within h from moment admission (n=70), 2, standard implemented (n=70). Hospital data analyzed. endpoint persistence congestion one or both circulatory circuits New York Heart Association Functional Classes III–IV, indicating ADHF.
 RESULTS: initial demographic clinical characteristics groups comparable. In 47% did not receive optimal drug (excluding iGLT-2) for chronic failure, no differences found this indicator (p=0.081). demonstrate significant effect likelihood an adverse outcome (odds ratio [OR]=0.88; 95% confidence interval [CI] 0.43–1.78, p=0.719). Multivariate analysis showed increase probability every 1000 pg/mL N-terminal propeptide brain natriuretic hormone (NT-proBNP) (OR=1.72, CI 1.37–2.17; p 0.001), blood urea per mmol/L (OR=1.54, 1.21–1.97; p=0.001), pulmonary hypertension (OR=7.08, 2.15–23.34; decrease 1% LVEF (OR=0.91, 0.84–0.99; p=0.031). sensitivity specificity model 91.3 85.1%, respectively.
 CONCLUSION: leading unfavorable include increased levels NT-proBNP urea, hypertension, decreased LVEF.